Cambridge, USA-based clinical-stage oncology company Immuneering (Nasdaq: IMRX) announced the appointment of Dr Igor ...

Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky ...

Hookipa Pharma (NASDAQ:HOOK – Get Free Report) is projected to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ...

Baker Brothers' 13F portfolio value decreased from $9.65B to $9.36B. Check out the portfolio's top holdings and notable stake ...

In other news, SVP Michael Alan Bell sold 2,209 shares of the company’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $49.87, for a total ...

RBC Capital的分析师已将HOOKIPA Pharma的股票评级从"优于大市"下调至"与大市同步"，并大幅下调目标价，从48.00美元降至2.00美元。此次降级是在HOOKIPA宣布重组计划之后做出的，该计划包括裁减80%的员工，并暂停其主要项目的临床开发。RBC ...

Hookipa Pharma (HOOK) (ISIN: US43906K2096)股票专题，提供今日Hookipa Pharma(HOOK) (ISIN: US43906K2096)股票最新股价查询，实时市场行情，走势图表，及Hookipa Pharma Inc(HOOK) (ISIN: US43906K2096)股票的专业技术分析，投资者论坛，历史交易数据，最新消息和未来价格预测。

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...